Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recurrent peptic ulceration

C W Howden1

  • 1Department of Internal Medicine, University of South Carolina School of Medicine, Columbia 29203-6808, USA.

Digestive Diseases (Basel, Switzerland)
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression.

Alimentary pharmacology & therapeutics·2014
Same author

Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care study.

Alimentary pharmacology & therapeutics·2013
Same author

Review article: current treatment options and management of functional dyspepsia.

Alimentary pharmacology & therapeutics·2012
Same author

Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.

Alimentary pharmacology & therapeutics·2009
Same author

Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.

Alimentary pharmacology & therapeutics·2009
Same author

Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers.

Alimentary pharmacology & therapeutics·2009
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Recurrent peptic ulcer disease management is revolutionized by understanding Helicobacter pylori. Targeting H. pylori and NSAIDs reduces ulcer recurrence, improving patient quality of life and reducing long-term treatment costs.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Therapeutics

Background:

  • Recurrent peptic ulcer disease presents significant clinical challenges.
  • Traditional treatments have evolved with new etiological insights.
  • Helicobacter pylori infection is a primary factor in peptic ulcer disease.

Purpose of the Study:

  • To discuss the evolving understanding of recurrent peptic ulcer disease.
  • To highlight the impact of Helicobacter pylori on ulcer recurrence.
  • To review rational management strategies for peptic ulcers.

Main Methods:

  • Literature review on peptic ulcer disease etiology and management.
  • Analysis of the role of Helicobacter pylori in ulcer pathogenesis.
  • Evaluation of non-steroidal anti-inflammatory drug (NSAID) related ulcers.

Related Experiment Videos

Main Results:

  • Most peptic ulcers are linked to H. pylori infection or NSAID use.
  • Understanding these factors is key to altering clinical approaches.
  • Effective management strategies can significantly reduce ulcer recurrence.

Conclusions:

  • Targeting H. pylori and NSAID use is crucial for managing recurrent peptic ulcers.
  • Improved patient quality of life is achievable through effective treatment.
  • Reduced need for continuous medical care offers long-term economic benefits.